Immunophenotyping of thyroid tumors identifies molecular markers altered during transformation of differentiated into anaplastic carcinoma

American Journal of Surgery

Volumn 201, Issue 5, 2011, Pages 580-586

  Wiseman, Sam M ^a   Griffith, Obi L ^b   Gown, Allen ^b,c   Walker, Blair ^b,d   Jones, Steven J M ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c PHENOPATH LABORATORIES   (United States)

^d ST PAUL S HOSPITAL   (Canada)

Author keywords

Anaplastic thyroid cancer; Anaplastic transformation; Differentiated thyroid cancer; Molecular markers; Thyroid cancer; Thyroid cancer progression

Indexed keywords

BETA CATENIN; DNA TOPOISOMERASE (ATP HYDROLYSING); KI 67 ANTIGEN; MOLECULAR MARKER; PROTEIN BCL 2; PROTEIN P53; THYROGLOBULIN; UVOMORULIN; VASCULOTROPIN;

ANAPLASTIC CARCINOMA; ANAPLASTIC THYROID CANCER; ARTICLE; DIAGNOSTIC ACCURACY; DIFFERENTIATED THYROID CANCER; DIFFERENTIATION; DISEASE ASSOCIATION; DOWN REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOM FOREST; SENSITIVITY AND SPECIFICITY; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TISSUE MICROARRAY; UPREGULATION;

EID: 79955685561     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2011.01.010     Document Type: Article

References (19)

1. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13:453-64.
2. Davies L, Welch HG. Thyroid cancer survival in the United States: observational data from 1973 to 2005. Arch Otolaryngol Head Neck Surg 2010;136:440-4.
3. Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 2010;22:395-404.
4. Kojic S, Strugnell SS, Wiseman SM. Anaplastic thyroid cancer: a comprehensive review of novel therapy. Exp Rev Anti-Cancer Ther. In press.
5. Wiseman SM, Masoudi H, Niblock P, et al. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol 2007;14:719-29. (Pubitemid 46175318)
6. Wiseman SM, Loree TR, Rigual NR, et al. Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck 2003;25:662-70. (Pubitemid 36909751)
7. O'Neill JP, Power D, Condron C, et al. Anaplastic thyroid cancer, tumorigenesis and therapy. Ir J Med Sci 2010;179:9-15.
8. Wiseman SM, Griffith OL, Deen S, et al. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg 2007;142:727-9.
9. Melck A, Masoudi H, Griffith OL, et al. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer. Ann Surg Oncol 2007;14:3403-11. (Pubitemid 350160133)
10. Parker RL, Huntsman DG, Lesack DW, et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Am J Clin Pathol 2002;117:723-8.
11. Edge SB. AJCC cancer staging manual. New York: Springer; 2009:87-96.
12. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993;114:1050-8.
13. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988;104:947-53. (Pubitemid 19011971)
14. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc (Ser B) 1995;57:289-300.
15. Giatromanolaki A, Lyberakidis G, Lyratzopoulos N, et al. Angiogenesis and angiogenic factor expression in thyroid cancer. J BUON 2010;15:357-61.
16. Mitselou A, Ioachim E, Peschos D, et al. E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies. Exp Oncol 2007;29:54-60. (Pubitemid 46713481)
17. Wiseman SM, Masoudi H, Niblock P, et al. Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg 2006;191:581-7.
18. von Wasielewski R, Rhein A, Werner M, et al. Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res 1997;57:2501-7. (Pubitemid 27255913)
19. Swanson T, Nanthakumar S, Bugis S, et al. Extrathyroidal anaplastic transformation case report & review. Cancer Ther 2008;6:491-4.